Project Grant R43IP001280
Award Date 9/30/26
Completion Date 9/29/28
Dollars Obligated $300K
Funding Federal Agency
Awarding Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Trellis Bioscience, Inc. $999,759 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to complete clinical trial preparation of TRL3D3, a human monoclonal antibody targeting respiratory syncytial virus. TRL3D3 is directed against the RSV G protein, which serves as the key attachment factor for infecting airway epithelial cells and modulates host immune response contributing to pathological...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute $3.679 million on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop self-assembling protein nanoparticles presenting stabilized hemagglutinin, neuraminidase, and M2E antigens for universal influenza vaccine development. The research addresses the structural and immunological challenges of creating a vaccine effective against both seasonal and pandemic...
- The National Institute of Allergy and Infectious Diseases awarded Sciogen LLC $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel therapeutics targeting respiratory syncytial virus (RSV) infection through G-receptor binding inhibition. The Phase I Small Business Innovation Research award funds evaluation of a new class of RSV inhibitors identified through high-throughput screening. Work includes assessment of biological...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $599,327 to Microbiotix, Inc. on September 22, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel benzyl-piperidine antifungal agents targeting intractable mucormycosis infections caused by drug-resistant Mucorales fungi. The project focuses on chemical optimization of a benzyl-piperidine series to improve drug-like properties and...
- The National Institute of Allergy and Infectious Diseases awarded $600,000 to Zylo Therapeutics, Inc. on September 12, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and optimize a nitric oxide-releasing microparticle formulation for topical treatment of chronic rhinosinusitis. Chronic rhinosinusitis, characterized by persistent inflammation and infection of the nasal cavity and paranasal sinuses, affects approximately 13 million U.S. adults....
- The National Heart, Lung, and Blood Institute awarded Cmtx Biotech Inc. $367,988 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a lung-specific, sulfonium lipid nanoparticle formulation of Incyclinide (CMT-3/SLNP) for treating acute respiratory distress syndrome in sepsis patients. This Phase I Small Business Technology Transfer project will evaluate the formulation and delivery of CMT-3/SLNP, a chemically modified, non-antibiotic tetracycline...
- The National Institute of Allergy and Infectious Diseases awarded Biotherapeutics, Inc. $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop oral first-in-class small-molecule therapeutics targeting a novel immunometabolic pathway for multiple sclerosis treatment. Biotherapeutics, Inc., a clinical-stage biotechnology company headquartered in Blacksburg, Virginia, will conduct Phase I research validating the safety, efficacy, and...
- The National Institute of Allergy and Infectious Diseases awarded Scripps Research Institute $865,432 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to dissect the mechanisms of action of saponin combination adjuvants for vaccine development. The award funds research into saponin/monophosphoryl lipid A nanoparticles (SMNP), cage-like nanostructures that combine saponins derived from the Chilean soapbark tree with a Toll-like receptor-4 agonist. The...
- The National Institute of Allergy and Infectious Diseases awarded Autonomous Therapeutics Inc. $1.981 million on September 10, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance a Phase II SBIR project translating AT191, an inhaled encrypted RNA (EncRNA) therapeutic candidate designed to prevent hospitalizations and deaths from SARS-CoV-2 variants. AT191 is a self-administered antiviral employing a platform-derived, first-in-class EncRNA technology that...
- The National Institute of Allergy and Infectious Diseases awarded Chitozan Health, LLC $320,600 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop innovative flame-retardant antimicrobial textiles for healthcare and protective applications. Chitozan Health will develop a dual-function textile finish combining antimicrobial and flame-retardant properties by leveraging chitosan and 0.25-micron silver chloride particles. The work involves...